RVPH News and Press, Reviva Pharmaceuticals Holdings Inc.

- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD) -Similar patents have also been granted in k...

2024-06-11 08:15:03 ET H.C. Wainwright analyst issues BUY recommendation for RVPH on June 11, 2024 06:40AM ET. The previous analyst recommendation was Buy. RVPH was trading at $1.45 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...

CUPERTINO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous ...

2024-05-28 08:45:21 ET More on Reviva Pharmaceuticals Reviva reports FDA acceptance of 4-week RECOVER-2 study for its schizophrenia treatment Read the full article on Seeking Alpha For further details see: Reviva Pharmaceuticals looks to raise $3M through direct ...

CUPERTINO, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous ...

CUPERTINO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous syste...

– 358 enrolled and 223 patients currently on treatment across sites in the USA, Europe and Asia – – Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label ext...

2024-05-14 10:50:19 ET More on Reviva Pharmaceuticals Reviva reports FDA acceptance of 4-week RECOVER-2 study for its schizophrenia treatment Seeking Alpha’s Quant Rating on Reviva Pharmaceuticals Historical earnings data for Reviva Pharmaceuticals Fin...

– Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Application (NDA) submission in schizophrenia – – Registrational RECOVER-2 trial expected to initiate Q2 2024; topline data expected Q3 2025 – ...

CUPERTINO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous syste...